[Expert consensus on population pharmacokinetics of Chinese medicine ( draft version for comments)].
In population pharmacokinetic (PPK) research of Chinese medicines with narrow therapeutic windows of toxicity, or when the target population is not homogeneous, or when there are frequent adverse reactions to parenterally administered Chinese medicine, select those that have a definite therapeutic effect, and in which the compositions of the toxic substances compositions are known, for study, and use complete PPK sampling design to take samples at specific time points. Use gas chromatography, HPLC, and LC-MS methods for the detection of target components. Finally, use total quantity statistical moment analysis, to account for each component of the PPK parameters. Thus, PPK model can reflect the overall trend of Chinese medicine, to provide the basis for reasonable clinical dosage adjustments.
Institute of Basic Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Yan-Ming
YM
Xie
Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Jian-Nong
JN
Wang
Hunan University of Chinese Medicine, Changsha 410208, China.
Fu-Yuan
FY
He
Institute of Basic Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Jun-Jie
JJ
Jiang
Third Hospital, Peking University, Beijing 100191, China.
Xin
X
Xiong
D032921:Consensus; D004365:Drugs, Chinese Herbal / Q000009:adverse effects / Q000493:pharmacokinetics*; D006801:Humans; D010599:Pharmacokinetics; D010601:Pharmacology, Clinical / Q000379:methods*; D012044:Regression Analysis
D004365:Drugs, Chinese Herbal